Skip to content

Study · Non-randomized trial · n = 5 · 1994

7 results

Benefits of continuous physiological pulsatile gonadotropin-releasing hormone therapy in women with polycystic ovarian syndrome.

Corenthal L, Von Hagen S, Larkins D, Ibrahim J, Santoro N

Fertility and sterility1 Jun 1994Cited by 8 (Europe PMC)

PMID8194612 (opens in a new tab)DOI10.1016/s0015-0282(16)56751-x (opens in a new tab)PepBankPUB-08194612
Publisher pagePubMedAsk about this study
Jump to 7 results

Summary

The text of this summary is not shown here, because the article license does not allow reuse. Read it at the source (opens in a new tab)

Text rights: Publisher copyright. Results still quote short attributed sentences.

Results from this study7

7 results from studies that gave the peptide. 7 results from people.

  1. 01HumanNon-randomized trialEfficacy outcome

    In women with clomiphene- and hMG-resistant PCOS, mean follicular phase LH was higher in the first cycle of pulsatile GnRH than in the second cycle.

    In plain wordsIn women with PCOS, LH hormone was higher in the first cycle of pulsed GnRH treatment than in the second cycle.

    Peptide
    Gonadorelin (GnRH, LHRH)
    Outcome
    IncreaseMean follicular phase LH, first versus second cycle
    Study

    n = 5

    Comparator
    Second ovulatory cycle on therapy
    Outcome group
    Sex hormones and fertility · Endocrine and hormones
    Studied dose
    100 ng/kg per bolus every 90 minutes · intravenous · two consecutive ovulatory cyclesAs given in this study (human).

    Measurements

    follicular phase LH AUC
    88 AUC units
    first cycles
    follicular phase LH AUC
    28 AUC units
    second cycles

    Source sentences

    Summary
    First ovulatory cycles on therapy were characterized by significantly increased mean follicular phase LH = 88 (arbitrary units area under the curve [AUC]) compared with second cycles (28 mean AUC units) and controls (13 mean AUC units).
    2 context sentences
    Summary · context
    Five women with well-characterized, clomiphene citrate (CC)- and hMG-resistant PCOS were treated with a 100 ng/kg per bolus of IV pulsatile GnRH (Lutrepulse; Ortho Pharmaceutical Corporation, Raritan, NJ) every 90 minutes for two consecutive ovulatory cycles.
    Summary · context
    These data were compared with a control group of normally cycling women.
  2. 02HumanNon-randomized trialEfficacy outcome

    In women with PCOS, mean follicular phase LH in the first cycle of pulsatile GnRH was higher than in normally cycling controls.

    In plain wordsIn women with PCOS, LH hormone in the first cycle of pulsed GnRH treatment was higher than in women with normal cycles.

    Peptide
    Gonadorelin (GnRH, LHRH)
    Outcome
    IncreaseMean follicular phase LH, first cycle versus controls
    Study

    n = 5

    Comparator
    Normally cycling women
    Outcome group
    Sex hormones and fertility · Endocrine and hormones
    Studied dose
    100 ng/kg per bolus every 90 minutes · intravenous · two consecutive ovulatory cyclesAs given in this study (human).

    Measurements

    follicular phase LH AUC
    88 AUC units
    first cycles
    follicular phase LH AUC
    13 AUC units
    controls

    Source sentences

    Summary
    First ovulatory cycles on therapy were characterized by significantly increased mean follicular phase LH = 88 (arbitrary units area under the curve [AUC]) compared with second cycles (28 mean AUC units) and controls (13 mean AUC units).
    2 context sentences
    Summary · context
    Five women with well-characterized, clomiphene citrate (CC)- and hMG-resistant PCOS were treated with a 100 ng/kg per bolus of IV pulsatile GnRH (Lutrepulse; Ortho Pharmaceutical Corporation, Raritan, NJ) every 90 minutes for two consecutive ovulatory cycles.
    Summary · context
    These data were compared with a control group of normally cycling women.
  3. 03HumanNon-randomized trialEfficacy outcome

    In women with PCOS, luteal phase E2 was higher in the first cycle of pulsatile GnRH than in the second cycle.

    In plain wordsIn women with PCOS, estradiol hormone was higher in the first cycle of pulsed GnRH treatment than in the second cycle.

    Peptide
    Gonadorelin (GnRH, LHRH)
    Outcome
    IncreaseLuteal phase estradiol, first versus second cycle
    Study

    n = 5

    Comparator
    Second ovulatory cycle on therapy
    Outcome group
    Sex hormones and fertility · Endocrine and hormones
    Studied dose
    100 ng/kg per bolus every 90 minutes · intravenous · two consecutive ovulatory cyclesAs given in this study (human).

    Source sentences

    Summary
    Luteal phase E2 (3,081 mean AUC units) was significantly increased in first cycles compared with second cycles (880 mean AUC units) and controls (1,562 mean AUC units in PCOS).
    2 context sentences
    Summary · context
    Five women with well-characterized, clomiphene citrate (CC)- and hMG-resistant PCOS were treated with a 100 ng/kg per bolus of IV pulsatile GnRH (Lutrepulse; Ortho Pharmaceutical Corporation, Raritan, NJ) every 90 minutes for two consecutive ovulatory cycles.
    Summary · context
    These data were compared with a control group of normally cycling women.
  4. 04HumanNon-randomized trialEfficacy outcome

    In women with PCOS, luteal phase E2 in the first cycle of pulsatile GnRH was higher than in normally cycling controls.

    In plain wordsIn women with PCOS, estradiol hormone in the first cycle of pulsed GnRH treatment was higher than in women with normal cycles.

    Peptide
    Gonadorelin (GnRH, LHRH)
    Outcome
    IncreaseLuteal phase estradiol, first cycle versus controls
    Study

    n = 5

    Comparator
    Normally cycling women
    Outcome group
    Sex hormones and fertility · Endocrine and hormones
    Studied dose
    100 ng/kg per bolus every 90 minutes · intravenous · two consecutive ovulatory cyclesAs given in this study (human).

    Source sentences

    Summary
    Luteal phase E2 (3,081 mean AUC units) was significantly increased in first cycles compared with second cycles (880 mean AUC units) and controls (1,562 mean AUC units in PCOS).
    2 context sentences
    Summary · context
    Five women with well-characterized, clomiphene citrate (CC)- and hMG-resistant PCOS were treated with a 100 ng/kg per bolus of IV pulsatile GnRH (Lutrepulse; Ortho Pharmaceutical Corporation, Raritan, NJ) every 90 minutes for two consecutive ovulatory cycles.
    Summary · context
    These data were compared with a control group of normally cycling women.
  5. 05HumanNon-randomized trialEfficacy outcome

    In women with PCOS, luteal phase E2 in the second cycle of pulsatile GnRH was elevated compared with normal, but not significantly.

    In plain wordsIn women with PCOS, estradiol in the second cycle of pulsed GnRH treatment was not significantly different from normal.

    Peptide
    Gonadorelin (GnRH, LHRH)
    Outcome
    No significant changeLuteal phase estradiol, second cycle versus normal
    Study

    n = 5

    Comparator
    Normally cycling women
    Outcome group
    Sex hormones and fertility · Endocrine and hormones
    Studied dose
    100 ng/kg per bolus every 90 minutes · intravenous · two consecutive ovulatory cyclesAs given in this study (human).

    Source sentences

    Summary
    Luteal phase E2 secretion was elevated in second cycles when compared with normal but not significantly.
    2 context sentences
    Summary · context
    Five women with well-characterized, clomiphene citrate (CC)- and hMG-resistant PCOS were treated with a 100 ng/kg per bolus of IV pulsatile GnRH (Lutrepulse; Ortho Pharmaceutical Corporation, Raritan, NJ) every 90 minutes for two consecutive ovulatory cycles.
    Summary · context
    These data were compared with a control group of normally cycling women.
  6. 06HumanNon-randomized trialEfficacy outcome

    In women with PCOS, the changes between the first and second cycles of pulsatile GnRH gave a more physiological pattern of gonadotropin and sex steroid secretion in the second cycle.

    In plain wordsIn women with PCOS, hormone patterns in the second cycle of pulsed GnRH treatment were closer to normal than in the first cycle.

    Peptide
    Gonadorelin (GnRH, LHRH)
    Outcome
    Not applicableGonadotropin and sex steroid pattern, second cycle
    Study

    n = 5

    Comparator
    First ovulatory cycle on therapy
    Outcome group
    Sex hormones and fertility · Endocrine and hormones
    Studied dose
    100 ng/kg per bolus every 90 minutes · intravenous · two consecutive ovulatory cyclesAs given in this study (human).

    Source sentences

    Summary
    The changes occurring between the first and second ovulatory cycles in women with PCOS resulted in a more physiological overall pattern of gonadotropin and sex steroid secretion in the second cycles.
    2 context sentences
    Summary · context
    Five women with well-characterized, clomiphene citrate (CC)- and hMG-resistant PCOS were treated with a 100 ng/kg per bolus of IV pulsatile GnRH (Lutrepulse; Ortho Pharmaceutical Corporation, Raritan, NJ) every 90 minutes for two consecutive ovulatory cycles.
    Summary · context
    These data were compared with a control group of normally cycling women.
  7. 07HumanNon-randomized trialEfficacy outcome

    In women with PCOS resistant to prior therapy, pulsatile GnRH led to two singleton pregnancies in the second cycle.

    In plain wordsIn women with PCOS, pulsed GnRH treatment led to two single-baby pregnancies in the second cycle.

    Peptide
    Gonadorelin (GnRH, LHRH)
    Outcome
    Not applicablePregnancies achieved
    Study

    n = 5

    Outcome group
    Sex hormones and fertility · Endocrine and hormones
    Studied dose
    100 ng/kg per bolus every 90 minutes · intravenous · two consecutive ovulatory cyclesAs given in this study (human).

    Source sentences

    Summary
    Two singleton pregnancies were achieved in the second cycle.
    2 context sentences
    Summary · context
    Five women with well-characterized, clomiphene citrate (CC)- and hMG-resistant PCOS were treated with a 100 ng/kg per bolus of IV pulsatile GnRH (Lutrepulse; Ortho Pharmaceutical Corporation, Raritan, NJ) every 90 minutes for two consecutive ovulatory cycles.
    Summary · context
    These data were compared with a control group of normally cycling women.

AI wrote and checked these results. AI can make mistakes, so check important results against the source.

Version history

PepBank keeps every version of the data on this study. Status changes from Retraction Watch, Europe PMC and Crossref are listed with their source.

  1. Version 2Current

    13 Oct 2026, 21:44 UTC

    Study results updated

  2. Version 1

    13 Oct 2026, 16:31 UTC

    First added · source update from Europe PMC

Subjects

Terms as the source lists them.

PepBank is a research reference. Talk to a doctor before you use any peptide.